4SC AGFRA:VSC PS Ratio is 0.11 as of Jun. 29, 2026, which is 100% below its 10-year median of 25.39. The stock has 7 warning signs investors should review.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 4SC AG's share price is €0.10.
4SC AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.94. Hence, 4SC AG's PS Ratio for today is 0.11.
Good Sign:
4SC AG stock PS Ratio (=0.11) is close to 10-year low of 0.11.
The historical rank and industry rank for 4SC AG's PS Ratio or its related term are showing as below:
FRA:VSC'
s PS Ratio Range Over the Past 10 Years
Min: 0.11 Med: 25.39 Max: 340
Current: 0.11
During the past 13 years, 4SC AG's highest PS Ratio was 340.00. The lowest was 0.11. And the median was 25.39.
FRA:VSC's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.29
vs FRA:VSC: 0.11
4SC AG's Revenue per Sharefor the
six
months ended in Dec. 2025 was €0.93.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.94.
Warning Sign:
4SC AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of 4SC AG was 2775.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 180.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -12.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -19.50% per year.
During the past 13 years, 4SC AG's highest 3-Year average Revenue per Share Growth Rate was 180.50% per year. The lowest was -71.30% per year. And the median was -33.40% per year.
Back to Basics: PS Ratio
4SC AG (FRA:VSC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
4SC AG PS Ratio Related Terms
4SC AG PS Ratio Historical Data
* Premium members only.
The historical data trend for 4SC AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 4SC AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4SC AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4SC AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where 4SC AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
4SC AG's Share Price of today is €0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4SC AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
4SC AG (FRA:VSC) has a PS Ratio of 0.11 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 4SC AG and its competitors. This is 100% below median its historical median of 25.39. Over the past decade, 4SC AG's PS Ratio has ranged from 0.11 to 340.00.
Is 4SC AG's PS Ratio too high?
4SC AG's current PS Ratio of 0.11 is 100% below median its 10-year median of 25.39. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 340.00. The Biotechnology industry median PS Ratio is 9.29. 4SC AG's value of 0.11 is 98.8% below this industry median.
How does 4SC AG's PS Ratio compare to VRTX and REGN?
4SC AG's PS Ratio of 0.11 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.29. 4SC AG's value of 0.11 is 98.8% below this benchmark. Historically, 4SC AG's own PS Ratio has ranged from 0.11 to 340.00 over the past decade. While the company's 10-year median is 25.39 vs. the industry median of 9.29, 4SC AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4SC AG's current PS Ratio of 0.11 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 4SC AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4SC AG's current PS Ratio is 0.11, which is 100% below median its own 10-year median of 25.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current PS Ratio of 0.11. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current PS Ratio is 0.11, which is 100% below median its 10-year median of 25.39 and 98.8% below the Biotechnology industry median of 9.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current PS Ratio is 0.11 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VSC has been successfully added to your 